| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years |
|
Blood Advances |
Aplastic Anemia |
| Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| ESCALATing care? Eltrombopag in pediatric aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
